Coronavirus disease 2019 in childhood and adolescence
© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021..
The coronavirus disease 2019 (COVID‑19) mostly occurs in children and adolescents as an asymptomatic infection. The course of the disease is usually mild or moderate. The estimated seroprevalence in Germany before the start of the vaccination program in children and adolescents was > 10%. Individual risk factors for a severe course are known. The COVID‑19-associated pediatric inflammatory multisystem syndrome (PIMS) is a very rare and severe disease with a favorable prognosis if diagnosed early and treated appropriately. The data situation on long-COVID syndrome in children and adolescents is still insufficiently defined and the incidence is not known. The primary source of infections in children and adolescents are household contacts. Transmission in school settings and other day care facilities play a subordinate role, at least in Germany.Two mRNA vaccines are currently approved in Europe for the prevention of COVID‑19 in children and adolescents above the age of 12 years. Except for the very rare occurrence of pericarditis/myocarditis in temporal association with the vaccination, especially in young men, the COVID‑19 vaccines are considered effective and safe in the age group 12-17 years. The Standing Vaccination Commission (STIKO) issued a vaccination recommendation for all 12-17-year-olds on 19 August 2021.
| Errataetall: |
CommentIn: Monatsschr Kinderheilkd. 2022;170(2):167-168. - PMID 35095116 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:169 |
|---|---|
| Enthalten in: |
Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde - 169(2021), 11 vom: 26., Seite 1010-1033 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
„Coronavirus disease 2019 (COVID‑19)“ im Kindes- und Jugendalter: Klinik, Epidemiologie und Impfprogramme |
|---|
| Beteiligte Personen: |
|---|
| Links: |
|---|
| Themen: |
COVID-19-Vaccination |
|---|
| Anmerkungen: |
Date Revised 18.02.2022 published: Print-Electronic CommentIn: Monatsschr Kinderheilkd. 2022;170(2):167-168. - PMID 35095116 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s00112-021-01326-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332584453 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332584453 | ||
| 003 | DE-627 | ||
| 005 | 20231225215854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00112-021-01326-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332584453 | ||
| 035 | |a (NLM)34720198 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Zepp, F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Coronavirus disease 2019 in childhood and adolescence |
| 246 | 3 | 3 | |a „Coronavirus disease 2019 (COVID‑19)“ im Kindes- und Jugendalter: Klinik, Epidemiologie und Impfprogramme |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Monatsschr Kinderheilkd. 2022;170(2):167-168. - PMID 35095116 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021. | ||
| 520 | |a The coronavirus disease 2019 (COVID‑19) mostly occurs in children and adolescents as an asymptomatic infection. The course of the disease is usually mild or moderate. The estimated seroprevalence in Germany before the start of the vaccination program in children and adolescents was > 10%. Individual risk factors for a severe course are known. The COVID‑19-associated pediatric inflammatory multisystem syndrome (PIMS) is a very rare and severe disease with a favorable prognosis if diagnosed early and treated appropriately. The data situation on long-COVID syndrome in children and adolescents is still insufficiently defined and the incidence is not known. The primary source of infections in children and adolescents are household contacts. Transmission in school settings and other day care facilities play a subordinate role, at least in Germany.Two mRNA vaccines are currently approved in Europe for the prevention of COVID‑19 in children and adolescents above the age of 12 years. Except for the very rare occurrence of pericarditis/myocarditis in temporal association with the vaccination, especially in young men, the COVID‑19 vaccines are considered effective and safe in the age group 12-17 years. The Standing Vaccination Commission (STIKO) issued a vaccination recommendation for all 12-17-year-olds on 19 August 2021 | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19-Vaccination | |
| 650 | 4 | |a Long-COVID | |
| 650 | 4 | |a Myocarditis | |
| 650 | 4 | |a Pediatric multisystem inflammatory disease, COVID‑19 related | |
| 650 | 4 | |a SARS-CoV‑2 infection | |
| 700 | 1 | |a Knuf, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde |d 1983 |g 169(2021), 11 vom: 26., Seite 1010-1033 |w (DE-627)NLM012890634 |x 0026-9298 |7 nnns |
| 773 | 1 | 8 | |g volume:169 |g year:2021 |g number:11 |g day:26 |g pages:1010-1033 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00112-021-01326-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 169 |j 2021 |e 11 |b 26 |h 1010-1033 | ||